



Sensitivity for colorectal cancer is 96.08%

Sensitivity for advanced precancerous lesions is **52.50**%

* Advanced precancerous lesions including advanced adenoma (tubular adenoma measuring ≥ 1 cm in greatest diameter, or adenoma with significant villous features), large serrated lesions or high-grade dysplasia.

Multi-target Fecal DNA Test for Colorectal Cancer Screening



COLOTECT[™] 3.0 is a combined human gene methylation and fecal occult blood non-invasive in vitro diagnostic (IVD) assay for qualitative detection of certain genes' methylation and fecal hemoglobin from human stool samples



COLOTECT[™] 3.0

Testing System Total Solution



COLOTECT[™] 3.0 Testing System Components



Stool Sample Collection Kit (CE marked)



Stool DNA Isolation Kit (CE marked)



Sample Pretreatment Kit for Methylation Detection (CE marked)



Combined Detection Kit for Human Genes Methylation and Fecal Occult Blood (CE marked)

Testing Reagents

Stool DNA Isolation Kit

• Stool Sample Collection Kit

• Sample Pretreatment Kit for Methylation Detection

• Sample Collection: Collect the sample and return the sample

• Sample Storage: Samples can be kept for a maximum of 4

• Combined Detection Kit for Human Genes

Methylation and Fecal Occult Blood

Sample Requirements

within 24 hours after collection

• Sample Type: Stool

Testing Instruments



MGISTP-7000 Sample Pre-treatment: 92samples/25min * Hands-on time not inculded



MGISP-NE384* Sample Isolation: 92*4 samples/50min DNA Bisulfite Conversion: 92*4 samples/70min * Hands -on time not included



qPCR* PCR Analysis: 92 samples/2h *COLOTECT will be compatible with a few PCR platforms



Reporting Software eration: 10000 samples/2s

Product Advantages



Sample collection process is designed with privacy and convenience in mind. Customers can collect stool samples in the comfort of their homes and mail samples back to the processing laboratories.



Non-invasive and painless test uses stool samples to perform early detection of colorectal cancer and does not require bowel preparation.



לה

The multi-biomarker DNA and FIT combined testing technology increases rate of detection of colorectal cancer and pre-cancerous lesions, offering ideal performance for colorectal cancer early screening.


BGI can provide entire end-to-end COLOTECT[™] 3.0 testing infrastructure.

Turnaround time



5~10 calendar days (from sample arriving at BGI lab to reporting)

nd Indications for U



COLOTECT \ge 3.0 in includios for 65e. COLOTECT \ge 3.0 is a noninvasive in vitro diagnostic (IVD) assay for qualitative detection of genes methylation and fecal hemoglobin from human stool sample. The kit is applicable to all people aged 40-75 who need colorectal cancer screening test result indicates that the subject may have colorectal cancer and/or advanced precancerous lesions (APL), and further colonoscopy is required. This assay is not a replacement for colonoscopy, and the test results of this kit should not be use basis for clinical diagnosis. Clinicians should comprehensively judge the results based on the patient's condition and other laboratory indicators.

to 42 days.

